Global Vaccine Market Outlook 2020
The pharmaceutical segment has faced diminishing prospects because of declining research and development productivity, stringent regulatory activities and generic competition for off patent products. On the contrary, vaccine segment has developed as highly profitable because of advancements in genomics and manufacturing technologies as well as increasing demand from emerging economies.
Meanwhile, continuous efforts have been put in by the biopharmaceutical companies to create tremendous opportunities for leading players to tap this market. Besides, vaccines have high entry barrier for generic players and potential to generate blockbuster sales, which thereby allure the market players.
The report, “Global Vaccine Market Outlook 2020” provides an extensive research and in-depth analysis of the current status and future outlook of the global vaccine market. The market, which stood at US$ 30.5 Billion in 2013, is expected to grow at a CAGR of around 12% during 2013-2020.
In our report, we have segmented the global vaccine market based on 16 therapeutic categories, and market for each has been forecasted. For each therapeutic segment, marketed product portfolio, pipeline products along with recent developments have been analyzed. Followed by this, important geographies have been highlighted along with their current and future markets outlook till 2020. The report also covers advanced stage pipeline analysis of key players, which list down the vaccines already in Phase III trials. Through this, our analysts have conducted a thorough opportunity assessment in various therapeutic categories and regions to clearly highlight avenues which offer maximum opportunities for growth.
In the end, various key players have been enlisted. Our team has analyzed each company’s strengths and weaknesses along with its vaccine portfolio and pipeline that will help the reader to better position his company vis-à-vis competition.
Meanwhile, continuous efforts have been put in by the biopharmaceutical companies to create tremendous opportunities for leading players to tap this market. Besides, vaccines have high entry barrier for generic players and potential to generate blockbuster sales, which thereby allure the market players.
The report, “Global Vaccine Market Outlook 2020” provides an extensive research and in-depth analysis of the current status and future outlook of the global vaccine market. The market, which stood at US$ 30.5 Billion in 2013, is expected to grow at a CAGR of around 12% during 2013-2020.
In our report, we have segmented the global vaccine market based on 16 therapeutic categories, and market for each has been forecasted. For each therapeutic segment, marketed product portfolio, pipeline products along with recent developments have been analyzed. Followed by this, important geographies have been highlighted along with their current and future markets outlook till 2020. The report also covers advanced stage pipeline analysis of key players, which list down the vaccines already in Phase III trials. Through this, our analysts have conducted a thorough opportunity assessment in various therapeutic categories and regions to clearly highlight avenues which offer maximum opportunities for growth.
In the end, various key players have been enlisted. Our team has analyzed each company’s strengths and weaknesses along with its vaccine portfolio and pipeline that will help the reader to better position his company vis-à-vis competition.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. GLOBAL VACCINE MARKET OUTLOOK TO 2020
4. MAJOR VACCINES: CURRENT AND FUTURE MARKET ANALYSIS
4.1 Pneumococcal
4.2 Influenza
4.3 Cancer
4.4 Polio
4.5 Varicella
4.6 Rotavirus
4.7 Meningococcal
4.8 DTP
4.9 Hepatitis
4.10 Measles, Mumps, and Rubella (MMR)
4.11 Japanese Encephalitis
4.12 Tuberculosis
4.13 Malaria
4.14 Rabies
4.15 Typhoid
4.16 HIV
5. KEY GEOGRAPHICAL MARKETS
5.1 US
5.2 Europe
5.3 Japan
5.4 China
5.5 India
5.6 Brazil
6. PIPELINE ANALYSIS
7. COMPETITIVE LANDSCAPE
7.1 GSK
7.1.1 Business Overview
7.1.2 Vaccine Portfolio & Pipeline
7.1.3 Strengths and Weaknesses
7.2 Sanofi-Pasteur
7.2.1 Business Overview
7.2.2 Vaccine Portfolio & Pipeline
7.2.3 Strengths and Weaknesses
7.3 Pfizer
7.3.1 Business Overview
7.3.2 Vaccine Portfolio & Pipeline
7.3.3 Strengths and Weaknesses
7.4 Merck
7.4.1 Business Overview
7.4.2 Vaccine Portfolio & Pipeline
7.4.3 Strengths and Weaknesses
7.5 Novartis
7.5.1 Business Overview
7.5.2 Vaccine Portfolio & Pipeline
7.5.3 Strengths and Weaknesses
7.6 Emergent Biosolutions
7.6.1 Business Overview
7.6.2 Vaccine Portfolio & Pipeline
7.6.3 Strengths and Weaknesses
7.7 AstraZeneca Plc.
7.7.1 Business Overview
7.7.2 Vaccine Portfolio & Pipeline
7.7.3 Strengths and Weaknesses
7.8 Baxter International Inc.
7.8.1 Business Overview
7.8.2 Vaccine Portfolio & Pipeline
7.8.3 Strengths and Weaknesses
7.9 BioCSL (CSL Biotherapies)
7.9.1 Business Overview
7.9.2 Vaccine Portfolio & Pipeline
7.9.3 Strengths and Weaknesses
7.10 Dendreon Corporation
7.10.1 Business Overview
7.10.2 Vaccine Portfolio & Pipeline
7.10.3 Strengths and Weaknesses
7.11 Takeda Pharmaceutical Company Limited
7.11.1 Business Overview
7.11.2 Vaccine Portfolio & Pipeline
7.11.3 Strengths and Weaknesses
7.12 Crucell
7.12.1 Business Overview
7.12.2 Vaccine Portfolio & Pipeline
7.12.3 Strengths and Weaknesses
2. RESEARCH METHODOLOGY
3. GLOBAL VACCINE MARKET OUTLOOK TO 2020
4. MAJOR VACCINES: CURRENT AND FUTURE MARKET ANALYSIS
4.1 Pneumococcal
4.2 Influenza
4.3 Cancer
4.4 Polio
4.5 Varicella
4.6 Rotavirus
4.7 Meningococcal
4.8 DTP
4.9 Hepatitis
4.10 Measles, Mumps, and Rubella (MMR)
4.11 Japanese Encephalitis
4.12 Tuberculosis
4.13 Malaria
4.14 Rabies
4.15 Typhoid
4.16 HIV
5. KEY GEOGRAPHICAL MARKETS
5.1 US
5.2 Europe
5.3 Japan
5.4 China
5.5 India
5.6 Brazil
6. PIPELINE ANALYSIS
7. COMPETITIVE LANDSCAPE
7.1 GSK
7.1.1 Business Overview
7.1.2 Vaccine Portfolio & Pipeline
7.1.3 Strengths and Weaknesses
7.2 Sanofi-Pasteur
7.2.1 Business Overview
7.2.2 Vaccine Portfolio & Pipeline
7.2.3 Strengths and Weaknesses
7.3 Pfizer
7.3.1 Business Overview
7.3.2 Vaccine Portfolio & Pipeline
7.3.3 Strengths and Weaknesses
7.4 Merck
7.4.1 Business Overview
7.4.2 Vaccine Portfolio & Pipeline
7.4.3 Strengths and Weaknesses
7.5 Novartis
7.5.1 Business Overview
7.5.2 Vaccine Portfolio & Pipeline
7.5.3 Strengths and Weaknesses
7.6 Emergent Biosolutions
7.6.1 Business Overview
7.6.2 Vaccine Portfolio & Pipeline
7.6.3 Strengths and Weaknesses
7.7 AstraZeneca Plc.
7.7.1 Business Overview
7.7.2 Vaccine Portfolio & Pipeline
7.7.3 Strengths and Weaknesses
7.8 Baxter International Inc.
7.8.1 Business Overview
7.8.2 Vaccine Portfolio & Pipeline
7.8.3 Strengths and Weaknesses
7.9 BioCSL (CSL Biotherapies)
7.9.1 Business Overview
7.9.2 Vaccine Portfolio & Pipeline
7.9.3 Strengths and Weaknesses
7.10 Dendreon Corporation
7.10.1 Business Overview
7.10.2 Vaccine Portfolio & Pipeline
7.10.3 Strengths and Weaknesses
7.11 Takeda Pharmaceutical Company Limited
7.11.1 Business Overview
7.11.2 Vaccine Portfolio & Pipeline
7.11.3 Strengths and Weaknesses
7.12 Crucell
7.12.1 Business Overview
7.12.2 Vaccine Portfolio & Pipeline
7.12.3 Strengths and Weaknesses
LIST OF FIGURES:
Figure 3-1: Global - Vaccine Market (Billion US$), 2013-2020
Figure 4-1: Global - Causes of Deaths in Children (less 5 Years) among Low-income Countries (%), 2011
Figure 4-2: Global - Pneumococcal Vaccine Market (Billion US$), 2013-2020
Figure 4-3: Global - Influenza Vaccine Market (Billion US$), 2013-2020
Figure 4-4: Global - Cancer Vaccine Market (Billion US$), 2013-2020
Figure 4-5: Global - Polio Vaccine Market (Billion US$), 2013-2020
Figure 4-6: Global - Varicella Vaccine Market (Billion US$), 2013-2020
Figure 4-7: Global - Rotavirus Vaccine Market (Billion US$), 2013-2020
Figure 4-8: Global - Meningococcal Vaccine Market (Billion US$), 2013-2020
Figure 4-9: Global - Number of Diphtheria Incidences by Region (2009 & 2010)
Figure 4-10: Global - Number of nTetanus Incidences by Region (2009 & 2010)
Figure 4-11: Global - Number of tTetanus Incidences by Region (2009 & 2010)
Figure 4-12: Global - Number of Pertussis Incidences by Region (2009 & 2010)
Figure 4-13: Global - DTP Vaccine Market (Billion US$), 2013-2020
Figure 4-14: Global - Hepatitis Vaccine Market (Billion US$), 2013-2020
Figure 4-15: Global - Number of Measles Incidences by Region (2009 & 2010)
Figure 4-16: Global - Number of Mumps Incidences by Region (‘000), 2009 & 2010
Figure 4-17: Global - Number of Rubella Incidences by Region (2009 & 2010)
Figure 4-18: Global - MMR Vaccine Market (Million US$), 2013-2020
Figure 4-19: Global - Japanese Encephalitis Market (Million US$), 2013-2020
Figure 4-20: Global - Sources for Funding in HIV Vaccine R&D (%), 2011
Figure 5-1: Global - Vaccine Market by Region (%), 2013
Figure 5-2: Global - Vaccine Market by Region (%), 2020
Figure 5-3: US - Vaccine Market (Billion US$), 2013-2020
Figure 5-4: Europe - Vaccine Market (Billion US$), 2013-2020
Figure 5-5: Japan - Vaccine Market (Billion US$), 2013-2020
Figure 5-6: China - Vaccine Market (Billion US$), 2013-2020
Figure 5-7: India - Share of Domestic Consumption and Exports in Vaccine Market (2013)
Figure 5-8: India - Vaccine Market (Billion US$), 2013-2020
Figure 5-9: Brazil - Vaccine Market (Billion US$), 2013-2020
Figure 7-1: Global - Share of Key Players in Vaccine Market (2013)
Figure 7-2: GSK - Revenue Breakup by Business Segment (%), 2013
Figure 7-3: GSK - Vaccine Revenue Breakup by Product (%), 2013
Figure 7-4: Sanofi-Pasteur - Revenue Breakup by Business Segment (%), 2013
Figure 7-5: Sanofi-Pasteur - Vaccine Revenue Breakup by Product (%), 2013
Figure 7-6: Pfizer - Revenue Breakup by Business Segment (%), 2013
Figure 7-7: Pfizer - Revenue Breakup by Biopharmaceuticals (%), 2013
Figure 7-8: Merck - Revenue Breakup by Business Segment (%), 2013
Figure 7-9: Merck - Pharmaceutical Division Revenue by Segment (%), 2013
Figure 7-10: Novartis - Revenue Breakup by Business Segment (%), 2013
Figure 7-11: AstraZeneca - Revenue Breakup by Therapy Area (%), 2013
Figure 7-12: Baxter International - Revenue Breakup by Business Segment (%), 2013
Figure 7-13: BioCSL - Revenue Breakup by Business Segment (%), 2013
Figure 7-14: Takeda Pharmaceutical - Revenue Breakup by Business Segment (%), 2013
Figure 7-15: Crucell - Revenue Breakup by Vaccine Type (%), 2010
Figure 3-1: Global - Vaccine Market (Billion US$), 2013-2020
Figure 4-1: Global - Causes of Deaths in Children (less 5 Years) among Low-income Countries (%), 2011
Figure 4-2: Global - Pneumococcal Vaccine Market (Billion US$), 2013-2020
Figure 4-3: Global - Influenza Vaccine Market (Billion US$), 2013-2020
Figure 4-4: Global - Cancer Vaccine Market (Billion US$), 2013-2020
Figure 4-5: Global - Polio Vaccine Market (Billion US$), 2013-2020
Figure 4-6: Global - Varicella Vaccine Market (Billion US$), 2013-2020
Figure 4-7: Global - Rotavirus Vaccine Market (Billion US$), 2013-2020
Figure 4-8: Global - Meningococcal Vaccine Market (Billion US$), 2013-2020
Figure 4-9: Global - Number of Diphtheria Incidences by Region (2009 & 2010)
Figure 4-10: Global - Number of nTetanus Incidences by Region (2009 & 2010)
Figure 4-11: Global - Number of tTetanus Incidences by Region (2009 & 2010)
Figure 4-12: Global - Number of Pertussis Incidences by Region (2009 & 2010)
Figure 4-13: Global - DTP Vaccine Market (Billion US$), 2013-2020
Figure 4-14: Global - Hepatitis Vaccine Market (Billion US$), 2013-2020
Figure 4-15: Global - Number of Measles Incidences by Region (2009 & 2010)
Figure 4-16: Global - Number of Mumps Incidences by Region (‘000), 2009 & 2010
Figure 4-17: Global - Number of Rubella Incidences by Region (2009 & 2010)
Figure 4-18: Global - MMR Vaccine Market (Million US$), 2013-2020
Figure 4-19: Global - Japanese Encephalitis Market (Million US$), 2013-2020
Figure 4-20: Global - Sources for Funding in HIV Vaccine R&D (%), 2011
Figure 5-1: Global - Vaccine Market by Region (%), 2013
Figure 5-2: Global - Vaccine Market by Region (%), 2020
Figure 5-3: US - Vaccine Market (Billion US$), 2013-2020
Figure 5-4: Europe - Vaccine Market (Billion US$), 2013-2020
Figure 5-5: Japan - Vaccine Market (Billion US$), 2013-2020
Figure 5-6: China - Vaccine Market (Billion US$), 2013-2020
Figure 5-7: India - Share of Domestic Consumption and Exports in Vaccine Market (2013)
Figure 5-8: India - Vaccine Market (Billion US$), 2013-2020
Figure 5-9: Brazil - Vaccine Market (Billion US$), 2013-2020
Figure 7-1: Global - Share of Key Players in Vaccine Market (2013)
Figure 7-2: GSK - Revenue Breakup by Business Segment (%), 2013
Figure 7-3: GSK - Vaccine Revenue Breakup by Product (%), 2013
Figure 7-4: Sanofi-Pasteur - Revenue Breakup by Business Segment (%), 2013
Figure 7-5: Sanofi-Pasteur - Vaccine Revenue Breakup by Product (%), 2013
Figure 7-6: Pfizer - Revenue Breakup by Business Segment (%), 2013
Figure 7-7: Pfizer - Revenue Breakup by Biopharmaceuticals (%), 2013
Figure 7-8: Merck - Revenue Breakup by Business Segment (%), 2013
Figure 7-9: Merck - Pharmaceutical Division Revenue by Segment (%), 2013
Figure 7-10: Novartis - Revenue Breakup by Business Segment (%), 2013
Figure 7-11: AstraZeneca - Revenue Breakup by Therapy Area (%), 2013
Figure 7-12: Baxter International - Revenue Breakup by Business Segment (%), 2013
Figure 7-13: BioCSL - Revenue Breakup by Business Segment (%), 2013
Figure 7-14: Takeda Pharmaceutical - Revenue Breakup by Business Segment (%), 2013
Figure 7-15: Crucell - Revenue Breakup by Vaccine Type (%), 2010
LIST OF TABLES:
Table 4-1: Pneumococcal Vaccine Market - Key Players and Vaccines
Table 4-2: Key Pneumococcal Vaccines in Pipeline
Table 4-3: Influenza Vaccine Market - Key Players and Vaccines
Table 4-4: Key Influenza Vaccines in Pipeline
Table 4-5: Global - Cancer Statistics in More Developed and Less Developed Regions (2008)
Table 4-6: Cancer Vaccine Market - Key Players and Vaccines
Table 4-7: Key Cancer Vaccines in Pipeline
Table 4-8: Polio Vaccine Market - Key Players and Vaccines
Table 4-9: Key Polio Vaccines in Pipeline
Table 4-10: Varicella Vaccine Market - Key Players and Vaccines
Table 4-11: Rotavirus Vaccine Market - Key Players and Vaccines
Table 4-12: Key Rotavirus Vaccines in Pipeline
Table 4-13: Meningococcal Vaccine Market - Key Players and Vaccines
Table 4-14: Key Meningococcal Vaccines in Pipeline
Table 4-15: DTP Vaccine Market - Key Players and Vaccines
Table 4-16: Key DTP Vaccines in Pipeline
Table 4-17: Hepatitis Vaccine Market - Key Players and Vaccines
Table 4-18: Key Hepatitis Vaccines in Pipeline
Table 4-19: MMR Vaccine Market - Key Players and Vaccines
Table 4-20: Key MMR Vaccines in Pipeline
Table 4-21: Japanese Encephalitis Vaccine Market - Key Players and Vaccines
Table 4-22: Key Japanese Encephalitis Vaccines in Pipeline
Table 4-23: Tuberculosis Vaccine Market - Key Players and Vaccines
Table 4-24: Key Tuberculosis Vaccines in Pipeline
Table 4-25: Key Malaria Vaccines in Pipeline
Table 4-26: Rabies Vaccine Market - Key Players and Vaccines
Table 4-27: Key Rabies Vaccines in Pipeline
Table 4-28: Typhoid Vaccine Market - Key Players and Vaccines
Table 4-29: Key Typhoid Vaccines in Pipeline
Table 4-30: Global - Number of HIV/AIDS Patients by Region (2009)
Table 4-31: Key HIV Vaccines in Pipeline
Table 5-1: China - Vaccine Classification
Table 6-1: Vaccine Pipeline Analysis
Table 7-1: GSK - Vaccines Portfolio
Table 7-2: GSK - Vaccines in Pipeline
Table 7-3: GSK - Strengths and Weaknesses
Table 7-4: Sanofi-Pasteur - Vaccines Portfolio
Table 7-5: Sanofi-Pasteur - Vaccines in Pipeline
Table 7-6: Sanofi-Pasteur - Strengths and Weaknesses
Table 7-7: Pfizer - Vaccines Portfolio
Table 7-8: Pfizer - Vaccines in Pipeline
Table 7-9: Pfizer - Strengths and Weaknesses
Table 7-10: Merck - Vaccines Portfolio
Table 7-11: Merck - Vaccines in Pipeline
Table 7-12: Merck - Strengths and Weaknesses
Table 7-13: Novartis - Vaccines Portfolio
Table 7-14: Novartis - Vaccines in Pipeline
Table 7-15: Novartis - Strengths and Weaknesses
Table 7-16: Emergent Biosolutions - Vaccines Portfolio
Table 7-17: Emergent Biosolutions - Vaccines in Pipeline
Table 7-18: Emergent Biosolutions - Strengths and Weaknesses
Table 7-19: AstraZeneca - Vaccines Portfolio
Table 7-20: AstraZeneca - Vaccines in Pipeline
Table 7-21: AstraZeneca - Strengths and Weaknesses
Table 7-22: Baxter International - Vaccines Portfolio
Table 7-23: Baxter International - Vaccines in Pipeline
Table 7-24: Baxter International - Strengths and Weaknesses
Table 7-25: BioCSL - Vaccines Portfolio
Table 7-26: BioCSL - Strengths and Weaknesses
Table 7-27: Dendreon Corporation - Vaccines Portfolio
Table 7-28: Dendreon Corporation - Vaccines in Pipeline
Table 7-29: Dendreon Corporation - Strengths and Weaknesses
Table 7-30: Takeda Pharmaceutical - Vaccines Portfolio
Table 7-31: Takeda Pharmaceutical - Vaccines in Pipeline
Table 7-32: Takeda Pharmaceutical - Strengths and Weaknesses
Table 7-33: Crucell - Vaccines Portfolio
Table 7-34: Crucell - Vaccines in Pipeline
Table 7-35: Crucell - Strengths and Weaknesses
Table 4-1: Pneumococcal Vaccine Market - Key Players and Vaccines
Table 4-2: Key Pneumococcal Vaccines in Pipeline
Table 4-3: Influenza Vaccine Market - Key Players and Vaccines
Table 4-4: Key Influenza Vaccines in Pipeline
Table 4-5: Global - Cancer Statistics in More Developed and Less Developed Regions (2008)
Table 4-6: Cancer Vaccine Market - Key Players and Vaccines
Table 4-7: Key Cancer Vaccines in Pipeline
Table 4-8: Polio Vaccine Market - Key Players and Vaccines
Table 4-9: Key Polio Vaccines in Pipeline
Table 4-10: Varicella Vaccine Market - Key Players and Vaccines
Table 4-11: Rotavirus Vaccine Market - Key Players and Vaccines
Table 4-12: Key Rotavirus Vaccines in Pipeline
Table 4-13: Meningococcal Vaccine Market - Key Players and Vaccines
Table 4-14: Key Meningococcal Vaccines in Pipeline
Table 4-15: DTP Vaccine Market - Key Players and Vaccines
Table 4-16: Key DTP Vaccines in Pipeline
Table 4-17: Hepatitis Vaccine Market - Key Players and Vaccines
Table 4-18: Key Hepatitis Vaccines in Pipeline
Table 4-19: MMR Vaccine Market - Key Players and Vaccines
Table 4-20: Key MMR Vaccines in Pipeline
Table 4-21: Japanese Encephalitis Vaccine Market - Key Players and Vaccines
Table 4-22: Key Japanese Encephalitis Vaccines in Pipeline
Table 4-23: Tuberculosis Vaccine Market - Key Players and Vaccines
Table 4-24: Key Tuberculosis Vaccines in Pipeline
Table 4-25: Key Malaria Vaccines in Pipeline
Table 4-26: Rabies Vaccine Market - Key Players and Vaccines
Table 4-27: Key Rabies Vaccines in Pipeline
Table 4-28: Typhoid Vaccine Market - Key Players and Vaccines
Table 4-29: Key Typhoid Vaccines in Pipeline
Table 4-30: Global - Number of HIV/AIDS Patients by Region (2009)
Table 4-31: Key HIV Vaccines in Pipeline
Table 5-1: China - Vaccine Classification
Table 6-1: Vaccine Pipeline Analysis
Table 7-1: GSK - Vaccines Portfolio
Table 7-2: GSK - Vaccines in Pipeline
Table 7-3: GSK - Strengths and Weaknesses
Table 7-4: Sanofi-Pasteur - Vaccines Portfolio
Table 7-5: Sanofi-Pasteur - Vaccines in Pipeline
Table 7-6: Sanofi-Pasteur - Strengths and Weaknesses
Table 7-7: Pfizer - Vaccines Portfolio
Table 7-8: Pfizer - Vaccines in Pipeline
Table 7-9: Pfizer - Strengths and Weaknesses
Table 7-10: Merck - Vaccines Portfolio
Table 7-11: Merck - Vaccines in Pipeline
Table 7-12: Merck - Strengths and Weaknesses
Table 7-13: Novartis - Vaccines Portfolio
Table 7-14: Novartis - Vaccines in Pipeline
Table 7-15: Novartis - Strengths and Weaknesses
Table 7-16: Emergent Biosolutions - Vaccines Portfolio
Table 7-17: Emergent Biosolutions - Vaccines in Pipeline
Table 7-18: Emergent Biosolutions - Strengths and Weaknesses
Table 7-19: AstraZeneca - Vaccines Portfolio
Table 7-20: AstraZeneca - Vaccines in Pipeline
Table 7-21: AstraZeneca - Strengths and Weaknesses
Table 7-22: Baxter International - Vaccines Portfolio
Table 7-23: Baxter International - Vaccines in Pipeline
Table 7-24: Baxter International - Strengths and Weaknesses
Table 7-25: BioCSL - Vaccines Portfolio
Table 7-26: BioCSL - Strengths and Weaknesses
Table 7-27: Dendreon Corporation - Vaccines Portfolio
Table 7-28: Dendreon Corporation - Vaccines in Pipeline
Table 7-29: Dendreon Corporation - Strengths and Weaknesses
Table 7-30: Takeda Pharmaceutical - Vaccines Portfolio
Table 7-31: Takeda Pharmaceutical - Vaccines in Pipeline
Table 7-32: Takeda Pharmaceutical - Strengths and Weaknesses
Table 7-33: Crucell - Vaccines Portfolio
Table 7-34: Crucell - Vaccines in Pipeline
Table 7-35: Crucell - Strengths and Weaknesses
